HIV infection Bronchial Asthama
Conditions
Interventions
Sponsors
Kurume University School of Medicine. Division of Respirology, Neurology and rheumatology, Department of Medicine 1
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Over 20 year-old. 2.Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. 3.Subjects must be documented HIV-seropositivity (enzyme-linked immunosorbent assay confirmed with Western blot analysis or polymerase chain reaction. 4.Condition is stable at least 4 weeks over.
Exclusion criteria
Exclusion criteria: 1.Presence of a known pre-existing, clinically important lung condition. This includes current infection or a history of cancer. 2.Subjects can not read, comprehend,and write at a level sufficient to complete study related materials. 3.Severe bronchial asthma 4.Subjects who are pregnant or breastfeeding. 5.HIV virus was infected by blood components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Comobidity of bornchial asthma or atopic dermatitis in HIV positive patients. 2. To clarify the efficacy and safety of inhaled corticosteroids. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-1. To discover the factor attribute to bronchial asthma onset. 1-2. To evaluate the correlation between airway hyper-responsiveness and lung function and CD4 cell counts. 2-1. Can inhaled corticosteroid reduce the frequency of SABA inhaler use. 2-2. To clarify the correlation between CD4 cell counts and asthma therapy. | — |
Countries
Japan
Contacts
Public ContactMasaki Tominaga
Kurume University School of Medicine Division of Respirology, Neurology and rheumatology, Department of Medicine 1
Outcome results
None listed